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lenges and opportunities. Results: Only 22%-27% of payers and providers believe 
that personalized medicine is a “very important” strategic goal versus ~50% of large 
biopharma manufacturers. Although 47%-52% of all stakeholders have integrated 
staff with area expertise, fewer than 20% have developed a centralized focus on 
personalized medicine and only 8%-20% believe they have tools to evaluate its suc-
cess. Decision maker perspectives ranged broadly on its key benefits but included 
improved and more predictable outcomes and cost efficiencies. Approximately 30% 
of all stakeholders believe that personalized medicines will continue to receive pre-
mium pricing to justify ROI for this business approach. ConClusions: Although 
most stakeholders see value in personalized medicines, they struggle with practical 
implementation and need actionable strategies to characterize the value and impact 
of these technologies. The survey suggests that limited emphasis on infrastructure 
development and methods, heterogeneous value assessment, and misalignment 
of incentives remain key challenges to enabling care and economic efficiencies 
promised by this evolving treatment paradigm.
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objeCtives: Reliable price data could enable consumers to choose providers that 
offer better value than others, eventually leading to market-level gains in quality 
and efficiency. The objective of this study is to predict price-to-charge ratios (PCRs) 
for community hospital stays on the basis of charge data and information about 
individual stays, hospitals, market areas, and states. Methods: We used 2006 
Healthcare Cost and Utilization Project State Inpatient Databases from California, 
Florida, Massachusetts, Nevada, New Jersey, Virginia, West Virginia and Wisconsin. 
We predicted PCRs for major payer categories for over 1,000 community hospitals 
as a function of state, market, hospital, and patient characteristics using expo-
nential conditional mean models with a log link and gamma-distributed errors. 
The unit of analysis was the hospital. We used a two-stage iterative estimation in 
which equations are estimated individually and the errors saved. In the next step, 
each payer equation is estimated a second time with the first-stage errors of the 
other payer equations as new independent variables. We assessed goodness of fit 
through model characteristics and by assessing the match of actual and predicted 
PCRs. Results: Average demographic characteristics were significant predictors of 
PCRs for Medicare and Private insurance, but not for Medicaid or Self-Pay. Hospital 
characteristics were related to every PCR category. Critical-access hospitals and 
teaching hospitals were associated with significantly greater PCRs for Medicare, 
Medicaid, and Private insurance holders. Greater numbers of Medicare and Medicaid 
discharges were associated with significantly lower PCRs. Higher PCRs were most 
often associated with worse economic conditions and greater state generosity in 
Medicaid eligibility and spending. ConClusions: Inpatient encounter prices paid 
by Medicare, Medicaid, and private insurance can be estimated with acceptable 
accuracy for community hospital stays. Stays funded by other insurance types or 
by patients were harder to predict and simultaneously have almost no correlation 
with PCRs.
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bACkgRound: Over the last decade, evidence-based assessment of food and 
nutritional products has substantially accelerated, in a fast-moving market and 
regulatory environment. Specific evidence synthesis, epidemiological and phar-
maco-economic tools have been increasingly required, developed and used for 
HTA and public health decision support. objeCtives: This presentation high-
lights through case studies the specific needs, tools and challenges arising from 
health economic evaluations of nutritional products. Methods: To first set the 
scene of nutritional product assessment, the regulatory and HTA systems and 
guidelines in both Europe and the US will be described and potential differences 
with drugs or devices highlighted. Through a series of illustrative but representa-
tive case studies covering both health claims and medical nutrition, the specific 
data needs and statistical methods to analyse them will reviewed and discussed. 
Data and methods gaps will be highlighted and consequences on the market 
access strategies and tactics will be discussed. Results: Nutritional products 
would typically target a wider and heterogeneous group of population than 
common drugs. Furthermore, control of food/compound exposure and effect in 
observational and clinical studies is more challenging resulting in larger studies 
and requiring more stringent tracking of compliance. Data analysis then requires 
refined statistical models such as hierarchical models able to handle population 
variability. Safety issues are also expected to be minimal to make benefit/risk 
evaluation acceptable by regulators, so that risk studies and risk management 
tactics should be designed accordingly. Finally, pricing and reimbursement depend 
even more than drugs on how the compound is positioned and for which target 
population. CONCLUSION Standard tools for evidence synthesis and pharmaco-
economic tools applied to nutritional products market access need to be stretched 
to their best to handle the higher population heterogeneity and numerous market 
access options.
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treated as the “intelligence” of the incorporation process procedures in the pub-
lic health system. Efficacy refers to the benefic effect in experimental conditions; 
effectiveness mentions the benefic effect operating under the system’s conditions, 
i.e. the action field; and cost-effectiveness refers to the objective when confronted 
with the costs involved in bringing the procedure into the system. ConClusions: 
The evidence researched by the HTA area, and not individual medical decisions or 
judicial sentences, should lead the policies on public health. The need to study the 
process of judicialization of health through HTA is evident.
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The Association of Southeast Asian Nations or ASEAN consists of ten member 
states. In 2007, the ASEAN leaders determined that the ASEAN Community will be 
established by 2015. The ASEAN Community will become a region with free move-
ment of goods, services, investment, skilled labor, and freer flow of capital. Since 
the trend in medical tourism continues growing worldwide, countries in ASEAN 
are strongly encouraging medical tourism as well. In particular, the Thai govern-
ment is promoting Thailand as a major medical hub in Asia as part of an effort to 
expand and diversify exports. Thailand aims to make itself the leading medical hub 
and the center for medical tourism. In this paper, the establishment of the ASEAN 
Community together with the transformation of Thailand as a medical hub is evalu-
ated. There are some concerns for both Thai and international patients who will 
receive Thai health care services. The increased number of international patients 
from becoming a medical hub along with the forming of the ASEAN Community 
would affect pharmaceutical costs in Thailand and put extra strain on its health 
care system. In addition to the escalated number of foreign patients, the shortage of 
health care professionals and the problem of their distribution in the country would 
be exacerbated. Last, this paper discusses proposed alternatives for the issue. One 
alternative solution that might diminish the effect of rising pharmaceutical costs to 
Thai patients is that the Thai government needs to negotiate with pharmaceutical 
firms producing brand-name medicine on behalf of Thai public hospitals. To reduce 
the shortage of the health care professionals in Thailand, the restrictions on foreign 
health care professionals should be loosened.
PHP143
multi criteria decision analysis metHods in HealtH care: current 
status, good Practice and Future recommendations
Thokala P.1, Marsh K.2, Devlin N.3, van Til J.4, Reddy B.5, Baltussen R.6, IJzerman M.J.4
1University of Sheffield, Sheffield, UK, 2Evidera, London, UK, 3Office of Health Economics, London, 
UK, 4University of Twente, Enschede, The Netherlands, 5National Centre for Pharmacoeconomics, 
Dublin, Ireland, 6Radboud University, Nijmegen, Gelderland, The Netherlands
objeCtives: There has been increase in the number of multi-criteria decision analy-
sis (MCDA) applications in health care since 1990s but there is still confusion among 
potential users regarding their appropriate use and this paper reports on an expert 
MCDA meeting organised to address these issues. Methods: An expert meeting 
was held in 2013 in UK with 21 representatives from a variety of governmental, 
academic and pharmaceutical institutes, which had the objective to discuss the 
role, options and limitations of MCDA in health. Results: The key messages and 
good practice recommendations developed by the participants of the expert meeting 
are as follows: a) Problem structuring is key: it is recommended that enough time is 
allocated to understand and specify the decision problem under consideration, b) 
Numerical MCDA modelling is not always necessary: deliberative discourse with the 
performance matrix as a starting point is sufficient in some situations rather than 
numerical MCDA models, c) Variety of weighting and scoring techniques: There are 
a number of different methods to estimate the value scores and to elicit the weights 
but not all scoring methods and weighting techniques are suitable for every MCDA 
method, d) Visualisation/transparency is important: For the decision makers to have 
confidence in the MCDA model, the model outputs need to be adequately visualised 
and the model needs to be transparent, e) Uncertainty modelling: appropriate care 
needs to be taken in performing uncertainty analysis ConClusions: MCDA has 
already been used and is well suited to support a broad range of health care decision 
problems but there is a need to develop a framework to select the appropriate MCDA 
technique for specific health care decisions. Future work is underway to develop 
the guidelines for choosing the most appropriate MCDA method to be applied for a 
given health care decision problem.
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objeCtives: As the US health care system drives toward population-level goals 
for efficiency and effectiveness, demand persists for more personal care at the 
patient-level. Personalized medicine is an emerging business model that harnesses 
genomics and biotechnology aimed at tailoring therapies and interventions to indi-
vidual patient characteristics. Market stakeholders universally acknowledge the 
tectonic shift away from the historic blockbuster drug model to a more targeted 
model. To evaluate current insights and challenges, we surveyed key stakeholders 
and decisions makers across the health care industry. Methods: We conducted a 
survey of approximately 300 biopharma executives, payers, and providers in the US 
and EU to gain insight into their needs, perceptions, and readiness to shift toward 
a more robust personalized medicine approach. This original research is aimed 
to characterize current status of infrastructure, preparedness, adoption and value 
assessment around personalized medicine development and highlight key chal-
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was higher for open procedures (90 [4.85%] open versus 743 [0.67%] laparoscopic; 
p< 0.001). Independent risk factors for SSI included acute cholecystitis (odds ratio 
[OR], 1.53; 95% confidence interval [CI], 1.32–1.77), choledocholithiasis (OR, 1.44; 
95% CI, 1.10–1.88), open approach (OR, 5.51; 95% CI, 4.00–7.61) laparoscopic con-
verted to open approach (OR, 5.48; 95% CI, 3.99–7.54), and concurrent bile duct 
repair (OR, 4.76; 95% CI, 1.93–11.70). Females had significantly decreased risk of SSI 
(OR, 0.75; 95% CI, 0.65–0.88). ConClusions: Acute cholecystitis, choledocholithi-
asis, and concurrent bile duct repair were associated with increased risk of SSI 
after cholecystectomy, controlling for open surgery, age, and gender. Our findings 
suggest that stratification of SSI rates by these operative factors is important when 
comparing rates between facilities.
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objeCtives: Describe the prevalence of contraindications to chronic hepatitis C 
(CHC) treatment among CHC patients not receiving CHC treatment (direct-acting 
antiviral [DAA] protease inhibitors, peg-interferon alpha, or ribavirin). Methods: 
Adult patients with ≥ 2 CHC diagnoses (ICD-9-CM codes 070.44, 070.54, 070.70, 
070.71) and no DAA fills at any time in their claims history were selected from a 
de-identified US-based claims database (2010-2012); the first CHC diagnosis after 
5/13/2011 was defined as the index date. Patients with CHC treatment 6-months 
before or 12 months after the index date were excluded. All patients were required 
to have continuous eligibility and no claims for hepatitis B during the 6-months 
before (baseline) and 12-months after their index dates. Contraindications (based 
on a World Health Organization hepatitis C guide) during the baseline period were 
identified based on ICD-9 codes and described for the overall cohort as well as 
stratified by age (18-39; 40-49; 50-59; 60-69; 70-79; 80+). Results: There were 12,726 
untreated patients identified, of which 7,644 (60.1%) had ≥ 1 baseline contraindica-
tion to peg-interferon or ribavirin. Untreated patients were 56 years old on average 
and more often male (61%). Approximately 86.8% of the untreated cohort had no 
claim for any CHC treatment any time in their claims history. The most common 
contraindications included arterial hypertension (32.1%), hepatic decompensation 
(22.3%), major system impairment (19.2%), and psychiatric depression (11.0%). Age-
stratified results showed increasing prevalence of contraindications with age; rates 
of contraindications increased from 44.2% among patients 18-39 to 76.65% among 
patients 80 years old and older. ConClusions: A high proportion of untreated CHC 
patients had diagnoses for contraindicated conditions, and the prevalence of these 
contraindications increased with age.
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objeCtives: Acute pancreatitis (AP) is associated with significant morbidity and 
mortality, representing a severe economic burden for health care system. Numerous 
attempts were made to find medications able to inhibit secretion of pancreatic 
enzymes and/or inflammatory cytokines in patients with AP to prevent further 
destruction of pancreas. There exist some evidences demonstrating that a cyclooxy-
genase inhibitor lornoxicam may inhibit secretion of inflammatory cytokines. The 
objective of the study was to investigate if lornoxicam administration might be clini-
cally and economically beneficial in patients with AP. Methods: Patients with AP 
were admitted in a Moscow hospital in 2010-2011. All of them were treated according 
to existing Russian standards of AP treatment. Part of patients were administered 
with lornoxicam iv bid during the first 5 days of hospitalization (16-32 mg a day). 
The information on the patients was collected using electronic health records (EHR) 
and then analyzed. Due to differences in baseline characteristics of the groups 
of patients treated and non-treated with lornoxicam, propensity scores matching 
technique was used. Logistic regression model was built to calculate propensity to 
be treated with lornoxicam for each patient. Then mortality rates were compared for 
the matched cohorts treated and non-treated with lornoxicam. Finally, the cost of 
one prevented death was calculated. Results: Totally 264 patients were identified 
in EHR, lornoxicame was administered to 74 patients. Propensity scores adjusted 
mortality rate was 6.0% for lornoxicam group and 20.0% for control group (p= 0.037). 
Thus, administration of lornoxicam might prevent mortality in 14% patients with AP. 
The cost of the 5-day course of lornoxicam was 2,602 RUB (78 USD). Therefore, the 
cost of one prevented death due to AP was 18,586 RUB (556 USD). ConClusions: 
It was demonstrated that intravenous injections of lornoxicam in patients with AP 
was not only potentially life-saving, but also cost effective, given the low cost of 
one prevented death.
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objeCtives: To determine the Prevalence and risk factors of Hepatitis B & C 
among the Barbers and their regular shaving clients in the Hyderabad Barber 
Shops of Pakistan. Methods: A cross sectional study was conducted to deter-
mine the sero-prevalence of Hepatitis-B virus (HBV) and Hepatitis-C virus (HCV) 
among barbers and their clients in Hyderabad Sindh Pakistan and to assess their 
knowledge, attitude and practices regarding these two viruses and their mode of 
transmission. Sampling was done by using a-2-stage sampling techniques. A close 
Collaboration between stakeholders underpinned by dynamic information exchange 
is the prerequisite of a systems-based market. If other industry sectors such as 
consumer goods, finance and telecommunications serve as a model for systems-
thinking, we will expect novel linkages between health care stakeholders to become 
more prevalent as population health goals unifies incentives. While many acknowl-
edge the need to move toward a more integrated “systems thinking” approach – one 
that maps influence patterns, amplifies interdependencies, and drives collective 
outcomes, they struggle with actual implementation. A recent survey of close to 
300 Biopharma executives, EU and US Payers, and US providers reveals insight 
into their needs, their disparate perceptions, and their levels of confidence in the 
ability to shift to a systems-thinking collaborative culture. Approximately 25% of 
respondents stated they were not aligned with other stakeholders, though agree 
they need better alignment and foresee closer collaboration in the future. More 
than 70% of stakeholders believe data transparency and information-sharing is 
critically important to a successful and interoperable health care system, yet very 
few from each group were willing to demonstrate such transparency. Most health 
care industry stakeholders are ill prepared for the necessary trust-building activi-
ties required by this anticipated transition. A viable and sustainable information 
network provides the structure, aligned incentives and competitive collaboration the 
bricks and mortar, and trust the cornerstone. Until they can build that and foster a 
culture of transparency, they won’t achieve the cost and innovation benefits inher-
ent in these cross-industry partnerships. Further detail will be given on insights 
and challenges gleaned from interviewing large and small stakeholders as well as 
practical strategies, such as experimentation with data integration projects, to guide 
the transformation to a systems-thinking industry.
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objeCtives: To compare the relative efficacy and safety of golimumab, inflixi-
mab and adalimumab for the treatment of moderate-to-severe ulcerative colitis 
using indirect treatment comparison (ITC) meta-analysis. Methods: A system-
atic literature search identified five randomized controlled trials. Outcomes of 
interest included clinical remission, clinical response, mucosal healing, sustained 
remission/response, serious adverse events (SAEs), and discontinuation due to 
adverse events (DAEs). Data was synthesized using Bayesian indirect treatment 
comparison (ITC) meta-analysis. The analysis incorporated advanced intention-to-
treat with baseline priors to account for the alternative design of the golimumab 
trial. Results: After the induction phase, each treatment had significantly 
greater efficacy than placebo all endpoints, with the exception of adalimumab 
for mucosal healing. No statistical differences were observed between golimumab 
and infliximab. Adalimumab had significantly lower efficacy measures compared 
to infliximab for clinical remission (odds ratio [OR] 0.42, 95% credible interval 
[CrI] 0.17-0.97), clinical response (OR 0.45, 95% CrI 0.23-0.89), and mucosal healing 
(OR 0.46, 95% CrI 0.25-0.84) after the induction period. During the maintenance 
phase, each biologic agent exhibited significantly greater efficacy compared to 
placebo for clinical remission, clinical response, and mucosal healing. Golimumab 
100mg was significantly better than adalimumab for clinical response (OR 1.80, 
95% CrI 1.01-3.21) and mucosal healing at 54 weeks (OR 1.88, 95% CrI 1.01-3.49). No 
statistical differences were observed between adalimumab and infliximab. Both 
golimumab 100mg and infliximab were significantly better than adalimumab in 
terms of sustained clinical response (OR 2.40, 95% CrI 1.17-4.86 and OR 1.93, 95% CrI 
1.04-4.06), respectively. For SAEs, there were no statistical differences between any 
of the biologics and placebo. Although all biologics were generally safe, golimumab 
100mg had statistically significantly higher DAEs when compared to adalimumab 
(OR 2.09, 95% CrI 1.07-4.17). ConClusions: In the context of ITC meta-analysis, 
both golimumab and infliximab appear to demonstrate superior efficacy-safety 
profiles compared with adalimumab.
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objeCtives: Over 500,000 cholecystectomies are performed in the U.S. annually. 
The incidence of surgical site infection (SSI) is higher after open compared to 
laparoscopic cholecystectomy, but other procedural risk factors for SSI have not 
been well established. We investigated operative risk factors for SSI following 
cholecystectomy in a large cohort of privately insured patients. Methods: We 
performed a retrospective cohort study of persons aged 18–64 years with ICD-
9-CM procedure or CPT-4 codes for cholecystectomy from 1/1/2004–12/31/2010 
using commercial insurer claims data. Complex procedures and patients (e.g., 
cancer, end-stage renal disease) were excluded. SSIs occurring within 90 days 
after cholecystectomy were identified by ICD-9-CM diagnosis codes. Procedures 
in which SSI or septicemia was coded ≤ 30 days before surgery were also excluded. 
Multivariable logistic regression was used to determine independent risk factors 
for SSI, controlling for age. Results: A total of 113,138 cholecystectomy proce-
dures were identified; 76% were performed in females and the median age was 
43 years (range 18–64). A total of 833 (0.74%) SSIs occurred; the SSI incidence 
